BK-virus nephropathy

Summary

BK-virus nephropathy (MONDO:0022529) is a disease and 6 clinical trials. Top therapeutic interventions include traxivitug and potravitug. A subtype of hantavirus hemorrhagic fever with renal syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	BK-virus nephropathy
Mondo ID	MONDO:0022529
DOID	DOID:0040086
SNOMED CT	713886006
UMLS	C1697878
MedGen	352157
GARD	0010470
Is cancer (heuristic)	no

Also known as: BK virus nephropathy · BKN · kidney disease caused by BK polyomavirus · nephropathy caused by BK polyomavirus · nephropathy from BK virus · Polyomavirus nephropathy

Disease family

This is a subtype of hantavirus hemorrhagic fever with renal syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › renal infectious disease › hantavirus hemorrhagic fever with renal syndrome › BK-virus nephropathy

Related subtypes (3): Hantavirus hemorrhagic fever with renal syndrome, Seoul virus type, Hantavirus hemorrhagic fever with renal syndrome, Puumala virus type, Hantavirus hemorrhagic fever with renal syndrome, Dobrava-Belgrade virus type

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03456999	PHASE2	WITHDRAWN	Determine the Safety, Tolerability, and Efficacy of MAU868 for the Prevention of BK Virus Infection in Kidney Transplant Recipients
NCT04605484	PHASE2	COMPLETED	Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia
NCT05358106	PHASE1	COMPLETED	Assess Safety, Tolerability and Pharmacokinetics of AntiBKV in Healthy Adult Volunteers.
NCT02758288	Not specified	WITHDRAWN	BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach
NCT04506060	Not specified	UNKNOWN	Evaluation of Renal Pretransplant Serology for BK Virus on the Risk of Post-transplant Viral Reactivation
NCT06219616	Not specified	COMPLETED	Prediction of BK Virus Reactivation in Kidney Transplant Recipient

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TRAXIVITUG	2	1
POTRAVITUG	1	1